|
|
|
|
|
by anotherboffin
1048 days ago
|
|
Nice summary!
From my limited knowledge in case someone’s more interested. Don’t know if it’s different in oncology. Phase 1 is pretty big on safety: sentinel dosing, then gradually increasing doses until the established max is reached or until serious side effects show up. Generally also includes PK/PD aspects: what is the half-life, how long it’s detectable in the body, does this match the modeling? How is the drug eliminated? All this is used to refine the dosing (if need be) but also provides a lot of the information needed for the safety documentation. |
|